EmailFacebookLinkedInTwitterGoogle+
Oxford Biotheraputics
Cancer Therapy Development
Cancer Therapy Development

Advancing novel antibody-drug conjugates

Progressing portfolios of therapeutics from discovery through development and onto the market requires extensive clinical, regulatory and manufacturing expertise. Few biotechnology companies possess this infrastructure and rely on outsourced partners or major pharmaceutical companies to advance development programs.

Reflecting the significant potential of our cancer antibody-drug conjugates (ADCs) we have established a major innovative collaboration, which provides a strategic alternative to these traditional development routes. This unique approach is complemented by a number of partnerships with global pharmaceutical companies, which validate our proprietary cancer targeting and antibody discovery technologies.

menarini

Our innovative collaboration with multinational pharmaceutical company Menarini is transformational for Oxford BioTherapeutics, forging a new business model that progresses beyond traditional partnerships. This agreement combines our established research expertise with Menarini’s development and production capabilities, and provides both organisations with potential parallel portfolios of novel oncology ADCs.

Under the five-product agreement, Oxford BioTherapeutics provides proprietary antibody-based cancer therapies combining innovative targeting, antibody and arming technologies. These address different cancer indications via novel oncology targets identified with our OGAP® technology. Menarini provides investment of up to $1.1 billion and leads the clinical development and manufacturing of the treatments up to phase II / proof-of-concept. Both organisations will then complete development and commercialization in their respective territories, with Oxford BioTherapeutics responsible for North America and Japan, and Menarini targeting Europe, Asia and Latin America.

Boehringer-Logo

Our partnership with Boehringer Ingelheim exploits our proprietary target discovery system. Under the agreement, Oxford BioTherapeutics provides a range of validated targets for antibody-based cancer therapies, in preparation for full development and commercialization by Boehringer Ingelheim.